CD274 and neoplasm: Considering the possibility that BCG-induced PD-L1 overexpression on tumor tissues might contribute to the immune escape mechanism in BCG-resistant NMIBC patients, PD-1/PD-L1 blockade therapy may be clinically effective in combination with BCG as adjuvant therapy or as secondary therapy at relapse after BCG.